Annual EBITDA
-$205.11 M
-$76.62 M-59.63%
December 31, 2023
Summary
- As of February 10, 2025, TXG annual EBITDA is -$205.11 million, with the most recent change of -$76.62 million (-59.63%) on December 31, 2023.
- During the last 3 years, TXG annual EBITDA has risen by +$308.66 million (+60.08%).
- TXG annual EBITDA is now -1405.40% below its all-time high of -$13.63 million, reached on December 31, 2017.
Performance
TXG EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$23.69 M
+$2.49 M+9.52%
September 30, 2024
Summary
- As of February 10, 2025, TXG quarterly EBITDA is -$23.69 million, with the most recent change of +$2.49 million (+9.52%) on September 30, 2024.
- Over the past year, TXG quarterly EBITDA has increased by +$56.64 million (+70.51%).
- TXG quarterly EBITDA is now -1158.55% below its all-time high of -$1.88 million, reached on March 31, 2019.
Performance
TXG Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$131.06 M
+$56.64 M+30.18%
September 30, 2024
Summary
- As of February 10, 2025, TXG TTM EBITDA is -$131.06 million, with the most recent change of +$56.64 million (+30.18%) on September 30, 2024.
- Over the past year, TXG TTM EBITDA has increased by +$46.98 million (+26.39%).
- TXG TTM EBITDA is now -848.17% below its all-time high of -$13.82 million, reached on September 30, 2018.
Performance
TXG TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
TXG EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -59.6% | +70.5% | +26.4% |
| 3 y3 years | +60.1% | -180.2% | -432.9% |
| 5 y5 years | -93.3% | -642.7% | -527.4% |
TXG EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -734.0% | at low | -203.1% | +70.5% | -432.9% | +37.7% |
| 5 y | 5-year | -882.0% | +60.1% | -824.5% | +94.1% | -527.4% | +74.5% |
| alltime | all time | -1405.4% | +60.1% | -1158.5% | +94.1% | -848.2% | +74.5% |
10x Genomics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$23.69 M(-9.5%) | -$131.06 M(-30.2%) |
| Jun 2024 | - | -$26.18 M(-43.5%) | -$187.69 M(-10.8%) |
| Mar 2024 | - | -$46.31 M(+32.7%) | -$210.40 M(+2.6%) |
| Dec 2023 | -$205.11 M(+59.6%) | -$34.88 M(-56.6%) | -$205.11 M(+15.2%) |
| Sep 2023 | - | -$80.32 M(+64.3%) | -$178.04 M(+37.5%) |
| Jun 2023 | - | -$48.88 M(+19.2%) | -$129.52 M(-4.7%) |
| Mar 2023 | - | -$41.02 M(+424.9%) | -$135.92 M(+5.8%) |
| Dec 2022 | -$128.49 M(+422.4%) | -$7.81 M(-75.4%) | -$128.49 M(-0.5%) |
| Sep 2022 | - | -$31.81 M(-42.5%) | -$129.13 M(+21.3%) |
| Jun 2022 | - | -$55.28 M(+64.6%) | -$106.47 M(+98.1%) |
| Mar 2022 | - | -$33.59 M(+297.4%) | -$53.76 M(+118.6%) |
| Dec 2021 | -$24.59 M | -$8.45 M(-7.7%) | -$24.59 M(-94.1%) |
| Sep 2021 | - | -$9.15 M(+257.3%) | -$419.03 M(-10.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2021 | - | -$2.56 M(-42.1%) | -$469.87 M(-6.5%) |
| Mar 2021 | - | -$4.43 M(-98.9%) | -$502.28 M(-2.2%) |
| Dec 2020 | -$513.77 M(+2359.7%) | -$402.89 M(+571.6%) | -$513.77 M(+350.4%) |
| Sep 2020 | - | -$59.99 M(+71.5%) | -$114.07 M(+87.2%) |
| Jun 2020 | - | -$34.97 M(+119.6%) | -$60.93 M(+74.4%) |
| Mar 2020 | - | -$15.92 M(+399.3%) | -$34.93 M(+67.2%) |
| Dec 2019 | -$20.89 M(-80.3%) | -$3.19 M(-53.4%) | -$20.89 M(-77.2%) |
| Sep 2019 | - | -$6.85 M(-23.7%) | -$91.60 M(-7.1%) |
| Jun 2019 | - | -$8.97 M(+376.7%) | -$98.58 M(+10.0%) |
| Mar 2019 | - | -$1.88 M(-97.5%) | -$89.61 M(+2.1%) |
| Dec 2018 | -$106.08 M(+678.6%) | -$73.90 M(+434.7%) | -$87.73 M(+534.7%) |
| Sep 2018 | - | -$13.82 M | -$13.82 M |
| Dec 2017 | -$13.63 M | - | - |
FAQ
- What is 10x Genomics annual EBITDA?
- What is the all time high annual EBITDA for 10x Genomics?
- What is 10x Genomics annual EBITDA year-on-year change?
- What is 10x Genomics quarterly EBITDA?
- What is the all time high quarterly EBITDA for 10x Genomics?
- What is 10x Genomics quarterly EBITDA year-on-year change?
- What is 10x Genomics TTM EBITDA?
- What is the all time high TTM EBITDA for 10x Genomics?
- What is 10x Genomics TTM EBITDA year-on-year change?
What is 10x Genomics annual EBITDA?
The current annual EBITDA of TXG is -$205.11 M
What is the all time high annual EBITDA for 10x Genomics?
10x Genomics all-time high annual EBITDA is -$13.63 M
What is 10x Genomics annual EBITDA year-on-year change?
Over the past year, TXG annual EBITDA has changed by -$76.62 M (-59.63%)
What is 10x Genomics quarterly EBITDA?
The current quarterly EBITDA of TXG is -$23.69 M
What is the all time high quarterly EBITDA for 10x Genomics?
10x Genomics all-time high quarterly EBITDA is -$1.88 M
What is 10x Genomics quarterly EBITDA year-on-year change?
Over the past year, TXG quarterly EBITDA has changed by +$56.64 M (+70.51%)
What is 10x Genomics TTM EBITDA?
The current TTM EBITDA of TXG is -$131.06 M
What is the all time high TTM EBITDA for 10x Genomics?
10x Genomics all-time high TTM EBITDA is -$13.82 M
What is 10x Genomics TTM EBITDA year-on-year change?
Over the past year, TXG TTM EBITDA has changed by +$46.98 M (+26.39%)